Co-Diagnostics, Inc.的合资企业Cosara已正式在印度启动一项临床研究，旨在评估其基于聚合酶链反应（PCR）平台的结核病检测技术。这项研究标志着该诊断方案在关键市场向实际应用迈出了重要一步。
Co-Diagnostics, Inc.的合资企业Cosara已正式在印度启动一项临床研究，旨在评估其基于聚合酶链反应（PCR）平台的结核病检测技术。这项研究标志着该诊断方案在关键市场向实际应用迈出了重要一步。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.